3^rd International Conference on Microbiome, Probiotics & Gut Nutrition December 06-07, 2019 Vancouver, Canada

Biography:

Dr. Shrilakshmi Desiraju, Founder – CEO. Triphase Pharmaceuticals Pvt. Ltd. After relocating from Canada to India, Dr. Desiraju made Triphase Pharmaceuticals functional in 2009. She started her jouney of innovation with Triphase in the field of Probiotics . The first big challenge that Triphase solved was in eliminating the cold chain from the Probiotics industry. It filed a patent for a new technology by which Probiotics could withstand temperatures of upto 250 degrees. In one single stroke the company had eliminated any need for cold storage. Desiraju has been involved in the strategic planning and implementation of growth for her current organization. A state of art research and development wing for probiotic research at Mysore, INDIA since 2009. Desiraju has a MBA degree in Technology Commercialization from University of Alberta, Canada, a PhD degree in Medicinal Chemistry from the Vikram University INDIA, and post- doctoral experience from the Indian Institute of Science, INDIA. She has a strong publication record in both scientific and business publications and is recipient of several international awards. With a patented technology to its credit, Dr. Desiraju’s Triphase pharma has made a significant dent in the food industry dominated by large corporations.

Abstract:

Probiotics are vital bacteria that colonize the intestine and modify its microflora with benefits for the host. Development of foods with adequate doses of probiotics is a challenge even now as , several factors during processing and storage affect the viability of probiotics. The food and beverage market is still beset by issues of strain stability, low product shelf life, and challenges in the development of probiotic application technology. Major emphasis has been given to protect the microorganisms with the help of encapsulation technique, by addition of different protectants, and by alteration of processing and storage conditions , which in turn increases the cost of the product. Triphase’s Thermostable natural gut Probiotic strains have the inherent ability to withstand harsh manufacturing process upto 200OC ++ (depending upon strain), especially in Food, Beverage, Bakery and Pharma industries. The TSP strains so develop open a window of opportunity for the Industry where following USP can be applied:

A) Withstand High temperatures up to 200OC. – thereby Cold chain eliminated,

B) pH stable towards acidic stomach conditions,

C) These are non-encapsulated / No enteric Coated, multiple industry applications apart from Diary. Our probiotics are designed to fortify food and beverages and are being further developed as prescription pharmaceutical products to ameliorate the side effects of drug treatments for infectious disease, oral health, cancer, and diabetes immunity therapeutic area also. The platform technology for making them temperature stable Lactobacillus species is US patented. (US Patent no. # 100,58577B2). Canadian and European patent – pending.

Biography:

Dr. Gibson (Associate Professor, Biology, University of British Columbia, Okanagan Campus) studies how the gut microbiome develops in response to the environmental ques like diet and how this drives immunity. She was the recipient of an NSERC research scholar award, a UBC Killam research award and the Canadian Association of Gastroenterology 2018 Young Investigator Award. She has been the recipient of grant funding from the Bill and Melinda Gates Foundation, Canadian Foundation for Dietetic Research, NSERC, Crohns and Colitis Canada and Micheal Smith Foundation for Health Research Innovation to Commercialization. She has published 55 papers and has an H-index of 32.

Abstract:

Inflammatory bowel disease (IBD) is a major global health and economic burden, and the rapid surge in pediatric cases in Canada over the past decade is raising alarm bells. Current pharmaceutical therapies are often ineffective for long-term use and are associated with severe side effects. Therefore, new alternative therapies for IBD are urgently needed. Probiotic therapy is widely believed considered a potential treatment option. However, clinical trials using probiotics for IBD treatment have had inconsistent results, and improving conventional probiotics specifically for IBD treatment is needed. In IBD patients, the gut environment is unique, for example, it is highly inflamed; these properties may interfere with the growth, and therefore beneficial effects of probiotics. As such, current probiotics are most likely inefficient for IBD patients. A novel approach is to engineer designer probiotics that strategically target these limitations in IBD patients through techniques such as genetic engineering. We bioengineered BioPersist and BioColoniz, two patented designer probiotics (DP), specifically to treat IBD by improving colonization, and persistence, to enhance the efficacy and longevity of the beneficial effects of probiotics. We have generated strong preliminary data supporting the efficacy of DP in preclinical studies in reducing both primary outcomes of IBD, as well as associated comorbidities, including metabolic dysfunction and neuropsychiatric conditions.

Biography:

French medical/scientific expert, specialized in infectious and tropical diseases, NCDs and certified in Immunology and Pediatric, MBA in vaccinology and Public health . Lived multi-country medical “field “experience in Southeast Asia, West/Central/East Europe and Middle East. Speaking French, English, Russian, Italian, Czech, and Slovak with notion of Mandarin. Over 17 years of experience in pharmaceutical research and development for European and USA companies as Medical lead /Director of R&D and Medical independent consultant PP. Active member of various academic societies with focus on R&D innovation and partnership highlighting role immunology/immune-metabolism and genetics for innovative treatment, prevention and diagnostic in context of resistance to treatment. Member of advisory Health concern (India) and think tank group in order to attract attention to role of public health and accessible medical care, education and awareness .Years of expertise to work globally but recently more focused on BRICS as Medical advisor for scientific partnership, bringing new innovative concepts alive and getting them endorsed.

Abstract:

Microbiome is composed from 100.000 milliards of bacteria and its weight is around 2 kg. It forms protective barrier against pathogens (permeability) and interactive layer with inner host immune system and neuroendocrine system. It does play important role in development (training of host immune response), human and reproductive health and need to be consider in diagnostic and prevention of diseases. It is a complex and diverse bacterial community specific to each individual crucial for human health. It is involved in immune mediated response and evolution of various diseases such as metabolic ones (diabetes, obesity), inflammatory diseases, (inflammatory bowel diseases), neurodegenerative diseases, psychiatric/behavioral disorders, respiratory diseases (allergy & asthma), cystic fibrosis(measurable changes in gut microbiome functionality occur in CF patients compared to controls), aging,response to cancer treatment, lipid metabolism. The gut healthy microbiome is able to convert lipids,including fatty acids or cholesterol, leading to the production of metabolites with potential health effects. Microbiome under 3 years old fluctuates substantially and is more sensible to environmental factors than the adult microbiome. Lifestyle, sanitation, caesarean sections, antibiotic usage, immunizations or responsiveness to vaccines interact with microbiome. It has been studied that there is a “critical window”early in life during which the microbiome can be disrupted in a way that may favour the development of disease later in life and there is and increasing evidence concerning role of microbiome changes during early life impacting the development of intestinal and extra- intestinal diseases. There are several pediatric diseases associated with alterations of the intestinal microbiome like Athopy and Asthma, Obesity and IBD (Crohn disease and Ulcerative colitis). Antibiotic usage in early life can significantly impact the growth of otherwise dominant bacterial pyla in the human gut. Use of antibiotics can render infants susceptible to several diseases later in life according scientific evidence. Antimicrobials select for drug-resistant strains and their repeated use creates a host-specific reservoir of antimicrobial-resistance genes and organisms. Than as a risks linked with changed permeability and consequence of microbiome dysbalance might lead to invasion and subsequent diseases. (ex: Clostridium difficile infections). As an ilustration of microbiome modulation or intervention for direct post-antibiotic effect which might develop- Clostridium diff. infections there is a support to research and development of antibodies, vaccine development and meantime use of microbiome modulation - FT- faecal transplantation (with known limitations) in order to decrease also carriage of AR genes. Targeted and individually specific intervention along with phagotherapy is other alternatives under exploration. The advantage of phage cocktails is that they generally will contain phages that infect more types of bacteria, so a cocktail can treat more strains or species and thus have broader applications. However, better understanding and standardized approach evaluated in clinical trials still needed. Thousands succumb to untreatable superbug infections on a daily basis. Meantime 33,000 people die every year due to infections with antibiotic-resistant bacteria and real danger of post-antibiotic era exists. As noted previously, from long term perspective there is an impact on human health and increased risk for list of diseases noted above. Therefore microbiome (microbiome mediated response) from perspective of human health might be considered as a tool for diagnostic and prevention of several diseases as well. Given all those facts and reality of raising resistance to TB drugs, antivirals, antiparasitic drugs, anticancer drugs,resistance is considered as one of the most significant challenges the world faces today. Host immune response empowering (microbiome/metabolome mediated immune response including data helping to diagnostic and accurate microbiome targeted interventions), genetics and all alternatives to enhance immune response (vaccines, included those derived from microbiome) are possible alternatives to face it. Antibiotics need to be preserved and research supporting innovative research for new compounds protecting composition of microbiome and prevention of AR genes spread (veterinary medicine, environmental impact including) is important to consider.